BioSpace News Archive

The development of next-generation sequencing (NGS) technologies has revolutionized gene sequencing in terms of reproducibility and cost savings. This has resulted in the introduction of several advancements in NGS technology to promote its usage in clinical labs and hospitals. Most current innovations in this field revolve around simplifying the usage of seq-technology and making it more sophisticated. These factors have driven the uptake of NGS services across various end-users.

Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that Lawrence M. Blatt, Ph.D., MBA, Chairman and CEO of Aligos, will present in at the Jefferies Healthcare Conference.

Technological advancements and a rise in the prevalence of ophthalmic disorders are anticipated to boost the growth of the market.

Ensysce Biosciences, Inc. announced the initiation of PF614-103, ‘A Randomized, Double-blind, Placebo- and Active-Controlled Crossover Study to Evaluate the Intranasal Abuse Potential of PF614 Compared with Immediate-Release Oxycodone and Placebo in Non-Dependent Recreational Opioid Users’ is being conducted by Dr. Glen Apseloff, from Ohio Clinical Trials.

Rising number of complex surgical procedures performed and increasing technological advancements in surgical imaging systems are key factors driving market revenue growth

Geneoscopy Inc., today announced findings from an early cost-effectiveness modeling study that aimed to assess the total costs and health outcomes associated with the use of an investigational RNA-FIT biomarker panel versus multi-target stool DNA (mt-sDNA), fecal immunochemical test (FIT), and colonoscopy alone for the screening of colorectal cancer (CRC).

Rising awareness about therapeutic potential of stem cells, rapid advancements in stem cell preservation and storage technologies, and increasing burden of chronic diseases are key factors driving market growth

The market growth for eHealth is significantly driven by the increasing demand for blood pressure meters and care phone/social alarms from the rising geriatric population around the world.

The primary growth-driving factors for the market growth include the adoption of minimally invasive surgeries along with the high usage of these devices in the diagnosis of several chronic disorders including cancer and others.

Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Global Investment Conference.